TODAY'S NEWS

KEYNOTE-826 Pembrolizumab Plus Chemother...

The addition of pembrolizumab to chemotherapy prol...

---

DESTINY Breast03 Second-Line Trastuzumab...

Fam-trastuzumab deruxtecan-nxki (T-DXd) showed sta...

---

Adjuvant Pembrolizumab for High-Risk Sta...

Adjuvant pembrolizumab reduced the risk of disease...

---

MONALEESA-2 Ribociclib Plus Endocrine Th...

Results from the phase III MONALEESA-2 trial showe...

---

Relacorilant Plus Nab-Paclitaxel May Imp...

In the first randomized, controlled study to explo...

More News From Today

EDITORIALS & COMMENTARY

https://www.advancedpractitioner.com/issues/volume-11,-number-6-(aug-2020)/asco20-virtual-scientific-program-takeaways-for-the-advanced-practitioner.aspx

CAR T-cell therapy is rapidly emerging as a promising treatment for many hematologic malignancies...

---

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

---

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

---

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

---

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

---

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

---

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

---

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

---

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights

LATEST TWEETS

The impact of #COVID19 launched creative resp...

about 1 days ago via web

---

At a face-to-face event, you're limited to th...

about 5 days ago via web

---

Want to know more about #acutekidneyinjury as...

about 5 days ago via web

---

What more can we say? 👇👇👇👇 #JADPROLive ht...

about 6 days ago via web

---

Last opportunity to take advantage of great r...

about 6 days ago via web

More Tweets